August 03, 2023
12 min listen
Save
Healio Minute Podcast, Leukemia Edition: Top Headlines - Week of July 31, 2023
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have ‘best shot’ at remission for double refractory CLL; mortality factors among cancer survivors and more.
Read the full coverage here:
FDA approves Vanflyta for newly diagnosed acute myeloid leukemia
VIDEO: Liso-cel could have ‘best shot’ at remission for double refractory CLL
Community affluence, insurance mediate CV mortality among Black, white cancer survivors
VIDEO: MOLTO study probes combination therapy in Richter syndrome
Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome
References:
ASCO Annual Meeting
ASCO Annual Meeting
Press Release
Press Release
Sung H, et al. Int J Epidemiol. 2023;doi:10.1093/ije/dyad097.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Please see each study for relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
